The Managed Care Review Board™ - An Analysis of the Latest Treatments, Economic Value, and Benefit Designs for Oral Anticoagulation Therapy Web Activity


Distinguished Faculty Presenters
James Groce III, PharmD, CACP
Professor of Pharmacy Practice
Campbell University School of Pharmacy
Clinical Assistant Professor of Medicine
University of North Carolina School of Medicine
Clinical Pharmacy Specialist-Anticoagulation
Moses H. Cone Memorial Hospital

Click here for biography
James Kenney, Jr., RPh, MBA
Manager, Specialty and Pharmacy Contracts
Harvard Pilgrim Health Care



Click here for biography
Neil Minkoff, MD
Principal, FountainHead HealthCare
Chief Medical Officer
EmpiraMed, Inc.


Click here for biography
Fadia T. Shaya, PhD, MPH
Professor and Vice Chair for Academic Affairs PHSR
University of Maryland
School of Pharmacy


Click here for biography

Target Audience

Statement of Need/Program Overview 
The value proposition for oral anticoagulants can be realized in a number of ways: fewer clinically-significant events, fewer hospitalizations, fewer physician office visits, less disability, and generally improved work productivity and quality of life. Managed care pharmacists will benefit from education and training regarding the value-based benefit approach to the management of patients who require anticoagulation to prevent stroke and systemic thromboembolism. The Managed Care Review Board™ format features review of important, relevant therapeutic category information and features peer-to-peer exchange between a diverse group of managed care and clinical specialty faculty contributors. This interactive program is designed to engage the faculty and audience to develop solutions for managed care professionals to implement within their own setting to improve outcomes for patients requiring oral anticoagulation therapy. This approach supports managed care pharmacists by enhancing the results of their own health care organization's systematic literature reviews and analyses.

Educational Objectives
After completing this activity, the participant should be better able to:

ACCREDITATION

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Postgraduate Institute for Medicine and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

Accreditation Statement 
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - (0809-9999-16-144-H01-P)

Type of Activity
Knowledge

Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

Nursing Continuing Education

Credit Designation
This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter Reported Financial Relationship
James Groce III, PharmD, CACP

Consulting Fees: Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen Pharmaceuticals, Inc., Pfizer, Inc.
Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus): Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen Pharmaceuticals, Inc., Pfizer, Inc.
Contracted Research: Diagnostica Stago, Inc.

James Kenney, Jr., RPh, MBA No financial interest/relationships relating to the topic of this activity
Neil Minkoff, MD Consulting Fees: Bayer Corporation, Boehringer Ingelheim, EMD Serono, Inc, Novartis Pharmaceuticals Corporation, Novo Nordisk, Inc., Salix Pharmaceuticals Inc., Sanofi US, UCB, Inc., Vertex Pharmaceuticals Incorporated
Fadia Tohme-Shaya, PhD, MPH No financial interest/relationships relating to the topic of this activity

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Planner or Manager Reported Financial Relationship
Steven Casebeer, MBA No financial interest/relationship relating to the topic of this activity
Keith Engelke, PhD, MBA No financial interest/relationship relating to the topic of this activity
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period March 4, 2016 through September 30, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.